TICKERNERD
Menu
CYTKCYTKHealthcare · Biotechnology

CYTK Stock Forecast: Cytokinetics, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$74
+0.20% on the day

The 22 Wall Street analysts covering Cytokinetics, Inc. hold a median 12-month price target of $108 — +45.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 51 of 100 as at 12 Sept 2026 — in the upper half.

Market cap
$10.3B
Ticker Nerd rank
51 / 100
Median analyst target
$108
Analysts covering
22
Revenue$28.6M−57.1% y/y
Operating income−$179.2M
Net income−$198.8M
Free cash flow−$164.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−0.2%
1M
−3.5%
YTD
+16.1%
1Y
+38.4%
From 52W high
−15.5%
From 52W low
+55.1%
$48
$87
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CYTK stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Cytokinetics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
51 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
87
Revisions
87
Volatility
73
Value
70
Accruals
46
Quality
44
Growth
32
Size
15
Issuance
10

Momentum (87): The shares have been drifting up relative to others.

Issuance (10): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CYTK stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CYTK, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$40$60$80$100$120$140$160Oct 25Jan 26Apr 26Jul 26CYTKHigh $146Median $108Low $85

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says22 analysts
20 Buy2 Hold0 Sell
Low $85Median $108High $146

The green dot is the last close — the median target sits +45.7% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 5 moved their price target up and 2 moved it down.

DateFirmActionRatingTarget
31 Aug 2026HC Wainwright & Co.ReiteratesBuy$140
13 Aug 2026BarclaysMaintainsOverweight$95 → $110
13 Aug 2026BarclaysMaintainsOverweight—
13 Aug 2026JP MorganMaintainsOverweight$97 → $103
13 Aug 2026JP MorganMaintainsOverweight—
10 Aug 2026Truist SecuritiesMaintainsBuy$106 → $112
10 Aug 2026Truist SecuritiesMaintainsBuy—
7 Aug 2026CitizensMaintainsMarket Outperform$105 → $110
7 Aug 2026CitizensMaintainsMarket Outperform—
7 Aug 2026NeedhamMaintainsBuy—
7 Aug 2026NeedhamMaintainsBuy$102 → $112
7 Aug 2026RBC CapitalMaintainsOutperform$117 → $112
7 Aug 2026RBC CapitalMaintainsOutperform—
7 July 2026RBC CapitalMaintainsOutperform$119 → $117
7 July 2026RBC CapitalMaintainsOutperform—
29 June 2026UBSUpgradeBuy—
24 June 2026MizuhoMaintainsOutperform—
17 June 2026NeedhamReiteratesBuy—
19 May 2026CitigroupInitiatesBuy—
12 May 2026JP MorganMaintainsOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CYTK appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

CYTK vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Cytokinetics, Inc. returned +38.4% against +17.5% for the S&P 500, dividends included.

CYTK vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140160Oct 25Jan 26Apr 26Jul 26CYTKS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CYTK analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
6
Analysts cutting
0
Fundamentals

Cytokinetics, Inc. (CYTK) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−11.3×

Cheaper than 93% of US stocks

Price / sales
151.6×

Cheaper than 3% of US stocks

Price / book
−56.2×

Cheaper than 99% of US stocks

EV / EBITDA
−15.1×

Cheaper than 87% of US stocks

Growth & margins
Revenue growth (YoY)
−57.1%

Higher than 5% of US stocks

Earnings growth (YoY)
−57.1%

Higher than 9% of US stocks

Gross margin
80.5%

Higher than 91% of US stocks

Operating margin
−626.0%

Higher than 7% of US stocks

Net margin
−372.5%

Higher than 1% of US stocks

Returns & dividend
Return on equity
119.0%

Higher than 97% of US stocks

Return on assets
−28.1%

Higher than 15% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Cytokinetics, Inc. (CYTK) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Cytokinetics, Inc. has a market value of $10.3B and an enterprise value of $10.5B.

  • Revenue in the twelve months to 30 June 2026: $67.7M. The latest quarter shrank 57.1% year on year.

  • Net income over the same four quarters: −$894.0M, a −1321.1% net margin.

  • Diluted earnings per share, trailing twelve months: $−7.22.

  • Free cash flow in the twelve months to 30 June 2026: −$580.7M.

  • Shares outstanding: 138.8M.

  • Trailing P/E: −11.3×; forward P/E: −16.6× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Cytokinetics, Inc. employs 673 people — $101K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

CYTK vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CYTKCytokinetics, Inc.$10.3B
51
KRYSKrystal Biotech, Inc.$10.3B
80
APGEApogee Therapeutics, Inc.$10.2B
—
KYMRKymera Therapeutics, Inc.$9.6B
73
PTGXProtagonist Therapeutics, Inc.$9.5B
97
TECHBio-Techne Corp.$11.2B
94
AXSMAxsome Therapeutics, Inc.$11.4B
74

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Cytokinetics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CYTK news & analysis

Cytokinetics: Why Myqorzo Doesn't Make Me A Buyer Yet

Seeking Alpha · 14 Sept 2026neutral

Cytokinetics' stock remains under pressure despite Myqorzo sales rising 427.1% quarter-over-quarter to $25.3 million in the second quarter. The August 28 NEJM article revealed full Phase 3 ACACIA-HCM data showing Myqorzo's high efficacy in symptomatic nonobstructive HCM, where rival Camzyos failed, though the company faces competitive pressure from Bristol Myers Squibb's Camzyos.

Why it matters — CYTK watchers would care because Myqorzo's strong sales growth and favorable Phase 3 ACACIA-HCM data in nonobstructive HCM could affect the drug's competitive position against Camzyos and influence the company's outlook.

Cytokinetics Announces Call for Proposals for Ninth Annual Communications Grant Program

GlobeNewsWire · 14 Sept 2026neutral

Cytokinetics announced a call for proposals for its ninth annual Communications Grant Program, which provides communications and outreach support for patient advocacy organizations focused on cardiovascular diseases.

Why it matters — The program reflects Cytokinetics' ongoing engagement with cardiovascular patient communities, an area central to its business focus.

Cytokinetics, Incorporated (CYTK) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Seeking Alpha · 9 Sept 2026neutral

Cytokinetics, Incorporated presented at Citigroup's Biopharma Back to School Summit 2026, with the event's transcript made available via Seeking Alpha. The presentation covered the company's remarks at the industry conference.

Why it matters — A Cytokinetics watcher would care because the presentation transcript offers direct insight into the company's messaging and updates shared at a major biopharma investor conference.

Cytokinetics to Participate in September Investor Conferences

GlobeNewsWire · 2 Sept 2026neutral

Cytokinetics announced that members of its management team will participate in the Citi 2026 BioPharma Back to School Conference, including a fireside chat on September 9, 2026 in New York. The company also indicated participation in additional investor conferences during September.

Why it matters — Investor conference appearances give CYTK watchers opportunities to hear management discuss the company and its pipeline directly.

Can CYTK's Aficamten Strengthen Its HCM Growth Prospects?

Zacks Investment Research · 2 Sept 2026positive

Zacks reports that Cytokinetics' aficamten demonstrated additional benefits in hypertrophic cardiomyopathy (HCM) studies, strengthening its potential in both non-obstructive and obstructive disease.

Why it matters — Aficamten's expanded benefits in HCM could broaden Cytokinetics' growth prospects in the cardiomyopathy treatment market.

FAQ

Frequently asked questions about CYTK stock

What is the CYTK stock price forecast for 2026-2027?

The 22 Wall Street analysts covering Cytokinetics, Inc. have a median 12-month price target of $108, with estimates ranging from $85 to $146. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CYTK stock a buy right now?

Of the 22 analysts covering Cytokinetics, Inc., 20 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Cytokinetics, Inc. 51 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CYTK?

As at 12 Sept 2026, Cytokinetics, Inc. ranks 51 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (87 of 100).

Will CYTK stock go up?

No one can know that. What the data says: the median 12-month target from 22 analysts implies +45.7% from the last close, and Ticker Nerd's factor model ranks Cytokinetics, Inc. 51 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CYTK stock forecast for 2030?

No analyst covering Cytokinetics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CYTK are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $85 to $146 over the next 12 months.

How has CYTK stock performed over the past year?

Cytokinetics, Inc. returned +38.4% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Cytokinetics, Inc. do?

Cytokinetics, Incorporated is a specialty cardiovascular biopharmaceutical company focused on discovering, developing, and commercializing medicines that target muscle biology. Its current work centers on therapies for cardiac muscle dysfunction, particularly heart conditions in which the heart’s contractile performance is compromised.

What is the latest news on CYTK?

The most recent item we track (Seeking Alpha, 14 Sept 2026): "Cytokinetics: Why Myqorzo Doesn't Make Me A Buyer Yet". Cytokinetics' stock remains under pressure despite Myqorzo sales rising 427.1% quarter-over-quarter to $25.3 million in the second quarter. The August 28 NEJM article revealed full Phase 3 ACACIA-HCM data showing Myqorzo's high efficacy in symptomatic nonobstructive HCM, where rival Camzyos failed, though the company faces competitive pressure from Bristol Myers Squibb's Camzyos.

Company

About Cytokinetics, Inc.

Cytokinetics, Incorporated is a specialty cardiovascular biopharmaceutical company focused on discovering, developing, and commercializing medicines that target muscle biology. Its current work centers on therapies for cardiac muscle dysfunction, particularly heart conditions in which the heart’s contractile performance is compromised. The company markets MYQORZO, an oral cardiac myosin inhibitor for symptomatic obstructive hypertrophic cardiomyopathy, and is advancing additional drug candidates such as aficamten for broader hypertrophic cardiomyopathy use and omecamtiv mecarbil for heart failure. Cytokinetics also develops other muscle-directed candidates in clinical-stage programs, reflecting its emphasis on precision treatments for diseases affecting cardiac and skeletal muscle function. Headquartered in South San Francisco, California, Cytokinetics plays a specialized role in the biopharmaceutical market by focusing on muscle performance disorders within cardiovascular medicine.

CEO Mr. Robert I. Blum · 673 employees · United States · https://www.cytokinetics.com